Arcus Biosciences, Inc. (RCUS)
NYSE • Healthcare
Last close at November 18, 2026 at 21:00 UTC
Metrics Over Time
Where the Money Goes
Q3 2026Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
Arcus Biosciences trailed consensus on EPS but topped revenue expectations in the third fiscal quarter of 2026, reported November 4, 2026, as revenue fell 65% year over year to about $9.0 million (down from roughly $26.0 million a year ago). On the quarter’s consensus lines, EPS of -$1.00 trailed the -$0.89 estimate by $0.11, while revenue of $9.0 million topped the $7.6 million estimate, +19%. The company, which is advancing immuno-oncology and targeted oncology programs including etrumadenant, zimberelimab, domvanalimab, quemliclustat, and AB521, posted an operating loss of roughly $131.0 million alongside a net loss of about $128.0 million; net income improved 5% year over year from around -$135.0 million. Versus last year, EPS improved 21% from -$1.27. For the next period, consensus calls for EPS of -$0.86 on revenue of $5.5 million.
About Arcus Biosciences, Inc.
Arcus Biosciences, Inc. (NYSE: RCUS) is a clinical-stage biopharmaceutical company in biotechnology that discovers and aims to commercialize cancer therapies. In FY2025, the company recorded $247.0 million in revenue. Its drug portfolio centers on immuno-oncology and targeted treatment candidates for solid tumors and genetically defined disease.
Today's Snapshot
RCUS closed 3.8% lower on heavier trading than usual.
Trading Volume
Above 10d avg 1.3M
1.9M
vs S&P 500 Today
Strong Underperformance
-3.58%
Updated: November 18, 2026 at 21:26 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$17.42 - $23.40Sell
- RSI (14)28.99Buy
- Stochastic %K (14, 3, 3)1.85Buy
- MACD Level (12, 26)-1.52Sell
Peers & Related Assets
Get premium market insights delivered directly to your inbox.